DE1617865A1 - Process for the manufacture of anti-cancer drugs - Google Patents
Process for the manufacture of anti-cancer drugsInfo
- Publication number
- DE1617865A1 DE1617865A1 DE19661617865 DE1617865A DE1617865A1 DE 1617865 A1 DE1617865 A1 DE 1617865A1 DE 19661617865 DE19661617865 DE 19661617865 DE 1617865 A DE1617865 A DE 1617865A DE 1617865 A1 DE1617865 A1 DE 1617865A1
- Authority
- DE
- Germany
- Prior art keywords
- tumor
- manufacture
- cancer drugs
- vacuum
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 238000004182 chemical digestion Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Description
Verfahren zur Herstellung von arzneimitteln gegen Krebs Die experimentelle Krebsforschung beweist die Übertragbarkeit vieler Tumoren durch beimpfung von einem Individuum auf ein anderes. Auch bei Autotranspiantation können neue Tumoren entstehen. Hierauf beruht ein Vorurteil gegen die therapeutische Anwendung von Tumormaterial. Process for the preparation of drugs against cancer The experimental Cancer research proves the transferability of many tumors by inoculating one Individual to another. Autotranspants can also develop new tumors. A prejudice against the therapeutic use of tumor material is based on this.
Es hat sich nun aber gezeigt, dass am Wachstum undder Ausbreitung eines Tumors eine sich entwickelnde immunologische Toleranz mit Schuld trägt.It has now been shown, however, that the growth and spread of a tumor is to blame for developing immunological tolerance.
Diese Immuntoleranz kann man-durchbrechen, wenn man zunächst lymphatisches Gewebe auf den Krebspatienten überträgt und dann in Art einer aktiven Immunisierung die körpereigene Geschwulst unter Zusatz eines Adjuvans in geeigneter Dosierung wiederholt reinjiziert. Die Verwendung der körpereigenen Geschwulst ist wegen der geschwulst und damit individualspezifischen Geschwulstantigene erforderlich. Diese Behandlung muss über längere Zeitspannen hinweg erfolgen. Deshalb ist es notwendig, Geschwülste, die durch chirurgische Eingriffe entfernt oder reseziert werden, zu Dauerpräparaten zu verarbeiten.You can break through this immune tolerance if you first have a lymphatic system Tissue is transferred to the cancer patient and then in an active immunization manner the body's own tumor with the addition of an adjuvant in a suitable dosage reinjected repeatedly. The use of the body's tumor is because of the tumor and thus individual-specific tumor genes required. These Treatment must be carried out over long periods of time. Therefore it is necessary Growths that are removed or resected by surgery, increase To process permanent preparations.
Zur Vermeidung autokatalytischer Vorgänge muss die Konservierung unmittelbar nach der Entnahme erfolgen. Es soll möglichst die Ausgangsgeschwulst und ihre Metastasen erfasst werden, weil in Metastasen zusätzliche Antigenarten auftreten können. Bei der Verarbeitung ist es zweckmässig, durch sehr schonende Hydrolyse die Gewebezellen chemisch aufzuschliessen. Dadurch wird die Übertragbarkeit der Geschwulst beseitigt und ihre unmittelbare Antigenität verstärkt. Hierzu hat sich das Verfahren des Patents 1 090 821 bewährt. Bei diesem erfolgt die Aufschliessung der aus der Geschwulst hergestellten Trookenpulver mit Hilfe von Dämpfen chemischer Reagenzien im Vacuum bei Normaltemperatur. Solche Hydrolysate sind jahrelang haltbar und lassen sich dann in einer Adjuvanslösung jederzeit zur aktiven Itrunisierung des Patienten oder tibermittlertiere zur Herstellung eines Antikörperserums verwenden Verständlicherweise übersteigt die Herstellung solcher individueller-Präparate den Rahmen der klinischen ärztliche Tätigkeit und kann nur in Speziallaboratorien erfolgen. Beispiel Von dem Geschwulstpräparat eines bestimmten Patienten, das durch chirurgisuche Eingriffe entnommen wurde, wird der nicht zur histologischen Diagnose verwendete Anteil möglichst kurz nach der Entnahme unter sterilen Kautelen in kirschkerngrosse Stücke zerschnitten. Diese werden in flüssigem Stickstoff eingefroren und dann in Trockeneis (Kohlensäureschnee), das in flüssigem Stickstoff vorgekühlt ist, zum Versand gebracht. In einem Speziallaboratorium wird das Material erneut in flüssigem Stickstoff tiefgekühlt, in einer ebenfalls tiefgekühlten Mühle fein pulverisiert, dann gefriergetrocknet und anschliessend im Vacuum bei Zimmertemperatur dem Dampf von konzentrierter Schwefelsäure ausgesetzt. Dieser Schwefelsäuredampf wird auf dem Substrat mehrmals niedergeschlagen durch Verringerung des Vacuums. Zuletzt wird das Vacuum soweit erhöht, dass die nicht zur Reaktion gekommene Schwefelsäure verdampft und abgesaugt werden kann. Das Pulver wird dann unter Luftabschluss in Stickstoffatmosphäre bis zur Benutzung aufbewahrt. Unmittelbar vor der Applikation wird es in einer wässrigen Adjuvanslösung, einer kolloidalen Komplexverbindung aus Aluminiumhydroxyd und Kieselsäure in geeigneter Konzentrqtion aufgeschwemmt.To avoid autocatalytic processes, the preservation must be immediate after removal. If possible, the original tumor and its metastases should be identified because additional types of antigens can occur in metastases. at During processing, it is advisable to hydrolyse the tissue cells very gently to be chemically digested. This eliminates the transferability of the tumor and enhances their immediate antigenicity. To do this, the procedure of the patent 1 090 821 proven. With this, the decomposition takes place from the tumor Trooken powder produced with the help of vapors of chemical reagents in a vacuum at normal temperature. Such hydrolysates can be kept for years and can be then in an adjuvant solution at any time for active Itrunization of the patient or Understandably, using intermediate animals to produce an antibody serum the production of such individual preparations exceeds the scope of clinical medical activity and can only take place in special laboratories. example From the tumor preparation of a specific patient that was subjected to surgical interventions was removed, the portion not used for the histological diagnosis is, if possible, used shortly after removal, cut into pieces the size of a cherry stone under sterile conditions. These are frozen in liquid nitrogen and then in dry ice (carbon dioxide snow), which has been pre-cooled in liquid nitrogen. In a special laboratory the material is frozen again in liquid nitrogen, also in one Finely powdered in a frozen grinder, then freeze-dried and then exposed to the vapor of concentrated sulfuric acid in a vacuum at room temperature. This sulfuric acid vapor is deposited several times on the substrate Reduction of the vacuum. Finally, the vacuum is increased so much that it does not any sulfuric acid that has reacted can be evaporated and suctioned off. The powder is then stored under the exclusion of air in a nitrogen atmosphere until use. Immediately before application, it is in an aqueous adjuvant solution, a colloidal complex compound of aluminum hydroxide and silica in suitable Concentration bloated.
PatentansPrüche 1.) Verfahren zur Herstellung von Arzneimitteln gegen Krebs, dadurch gekennzeichnet, dass aus der individuellen Krebsgeschwulst eines Patienten und bz. oder deren Metastasen nach bekannten Verfahren der chirurgischen Entnahme, Konservierung und chemischen Aufschliessung, Extraktion bzw. Isolierung von Antigenen oder über Mittler tiere Antikörperseren zur Behandlung des entsprechenden patienten gewonnen werden. Claims 1.) Process for the production of drugs against Cancer, characterized in that from the individual cancer tumor one Patients and or. Or their metastases according to known surgical methods Collection, preservation and chemical digestion, extraction or isolation of antigens or via intermediate animals antibody sera for the treatment of the corresponding patients are won.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DET0030661 | 1966-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1617865A1 true DE1617865A1 (en) | 1971-09-02 |
Family
ID=7555751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19661617865 Pending DE1617865A1 (en) | 1966-03-12 | 1966-03-12 | Process for the manufacture of anti-cancer drugs |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE1617865A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2423223A1 (en) * | 1978-04-20 | 1979-11-16 | Mac Collester Duncan | VACCINE AND INJECTION DOSE FOR IMMUNOTHERAPY OF NEOPLASTIC DISEASE |
EP0010738A1 (en) * | 1978-10-25 | 1980-05-14 | A/S Alfred Benzon | Transfer factor and method for producing same |
EP0485652A1 (en) * | 1990-11-14 | 1992-05-20 | Theurer, Karl E., Prof.Dr.med. | Process to prepare vaccines against pathologic agents |
-
1966
- 1966-03-12 DE DE19661617865 patent/DE1617865A1/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2423223A1 (en) * | 1978-04-20 | 1979-11-16 | Mac Collester Duncan | VACCINE AND INJECTION DOSE FOR IMMUNOTHERAPY OF NEOPLASTIC DISEASE |
EP0010738A1 (en) * | 1978-10-25 | 1980-05-14 | A/S Alfred Benzon | Transfer factor and method for producing same |
EP0485652A1 (en) * | 1990-11-14 | 1992-05-20 | Theurer, Karl E., Prof.Dr.med. | Process to prepare vaccines against pathologic agents |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE915973C (en) | Process for the production of hemostatically acting plugs and bandages | |
Pegum et al. | Contact dermatitis from penetration of rubber gloves by acrylic monomer | |
Raisz | Regulation by calcium of parathyroid growth and secretion in vitro | |
Nagler et al. | The use of the electron microscope in diagnosis of variola, vaccinia, and varicella | |
Baldwin et al. | Tuberculosis, Bacteriology, Pathology and Laboratory Diagnosis: With Sections on Immunology, Epidemiology, Prophylaxis and Experimental Therapy | |
DE1617865A1 (en) | Process for the manufacture of anti-cancer drugs | |
Harington et al. | Dimethylnitrosamine in the human vaginal vault | |
EP0153995B1 (en) | Process for the mild sterilization with respect to microorganisms and viruses of biologically active substances, especially organ tissues for therapeutic use | |
Finn et al. | Failure of histamine to induce deciduomata in the rat | |
Pantelouris et al. | Autoradiographic studies on Fasciola hepatica L. | |
DD145705A1 (en) | METHOD OF GENERATING ORGAN SPECIFIC RETROVIRUS IMMUNE PREVENTION AGENTS FOR PROPHYLAXIS, THERAPY AND DIAGNOSTICS | |
von Brand et al. | Cestode calcareous corpuscles: phosphate relationships, crystallization patterns, and variations in size and shape | |
GB2101888A (en) | Vegetable/animal extracts | |
DE2819131C2 (en) | ||
Ferguson et al. | Identity of a Muscle-inhibiting Flavone in Lucerne | |
Tajima et al. | Morphology of meningopneumonitis virus exposed to penicillin as observed with the electron microscope | |
KR100833465B1 (en) | Extracting device of earthworm mucus and extracting method of earthworm mucus using the device | |
US2464240A (en) | Therapeutic material and method of obtaining the same | |
Worm et al. | Experiences in interpretation with exhumed material illustrated by a single case of morphine intoxication | |
SE8305665L (en) | PROCEDURE FOR PREPARING A SOLUTION FOR PHARMACEUTICAL USE CONTAINING NEW MULTIPLE IRON (III) -MIXING COMPLEX AS ACTIVE INGREDIENT | |
DE2126957B2 (en) | PROCESS FOR MANUFACTURING VACCINES AGAINST GAENSEHEPATITIS | |
Klauder et al. | The Wassermann test performed with chancre fluid as an aid to the early diagnosis of syphilis | |
DE2600442A1 (en) | Medicaments against tumours and blood diseases - from cell or tissue cultures | |
Parent et al. | Serological evidence supporting an etiological role for pseudomonas-like bacteria in Crohn's disease | |
Johnstone | An adhesive applicator for radium therapy |